DD293961B5 - Verfahren zur Herstellung von Tabletten und Kapseln - Google Patents

Verfahren zur Herstellung von Tabletten und Kapseln Download PDF

Info

Publication number: DD293961B5
Authority: DD; German Democratic Republic
Prior art keywords: tablets; powder; mixture; capsules; solvent
Prior art date: 1989-04-07

Application number

DD33947390A

Other languages

German (de)

English (en)

Inventor

Luigi Moro

Achille Fiori

Alberto Natali

Original Assignee

Poli Ind Chimica Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-07

Filing date

1990-04-05

Publication date

1994-11-10

1990-04-05 Application filed by Poli Ind Chimica Spa filed Critical Poli Ind Chimica Spa

1994-11-10 Publication of DD293961B5 publication Critical patent/DD293961B5/de

Links

238000000034 method Methods 0.000 title claims abstract description 18
239000002775 capsule Substances 0.000 title claims abstract description 15
230000008569 process Effects 0.000 title claims abstract description 15
238000002360 preparation method Methods 0.000 title claims abstract description 11
239000000203 mixture Substances 0.000 claims abstract description 27
239000008187 granular material Substances 0.000 claims abstract description 16
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
239000004480 active ingredient Substances 0.000 claims abstract description 13
238000002156 mixing Methods 0.000 claims abstract description 10
238000003825 pressing Methods 0.000 claims description 14
239000000843 powder Substances 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 11
238000001035 drying Methods 0.000 claims description 10
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 9
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 9
239000011976 maleic acid Substances 0.000 claims description 9
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 4
238000004090 dissolution Methods 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 3
150000007524 organic acids Chemical class 0.000 claims description 3
239000013557 residual solvent Substances 0.000 claims description 3
239000003125 aqueous solvent Substances 0.000 claims description 2
239000003380 propellant Substances 0.000 claims 2
239000003960 organic solvent Substances 0.000 claims 1
238000007873 sieving Methods 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
239000011877 solvent mixture Substances 0.000 claims 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 abstract description 10
229960002802 bromocriptine Drugs 0.000 abstract description 10
238000005469 granulation Methods 0.000 abstract description 6
230000003179 granulation Effects 0.000 abstract description 6
239000000047 product Substances 0.000 description 11
238000005516 engineering process Methods 0.000 description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
239000000243 solution Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000004806 packaging method and process Methods 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
229910021485 fumed silica Inorganic materials 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 4
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000008961 swelling Effects 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000008901 benefit Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000007614 solvation Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
241000221751 Claviceps purpurea Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
OZVBMTJYIDMWIL-UHFFFAOYSA-N LSM-1746 Chemical compound C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-UHFFFAOYSA-N 0.000 description 1
WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000004807 desolvation Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
229960003133 ergot alkaloid Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000011521 glass Substances 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
229940000596 parlodel Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000003672 processing method Methods 0.000 description 1
238000004080 punching Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DD33947390A 1989-04-07 1990-04-05 Verfahren zur Herstellung von Tabletten und Kapseln DD293961B5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT8920063A IT1235053B (it)	1989-04-07	1989-04-07	Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.

Publications (1)

Publication Number	Publication Date
DD293961B5 true DD293961B5 (de)	1994-11-10

Family

ID=11163518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD33947390A DD293961B5 (de)	1989-04-07	1990-04-05	Verfahren zur Herstellung von Tabletten und Kapseln

Country Status (9)

Country	Link
US (1)	US5066495A (it)
EP (1)	EP0391374B1 (it)
AT (1)	ATE114968T1 (it)
DD (1)	DD293961B5 (it)
DE (2)	DE391374T1 (it)
DK (1)	DK0391374T3 (it)
ES (1)	ES2029776T3 (it)
GR (1)	GR900300172T1 (it)
IT (1)	IT1235053B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2030174C (en) *	1990-01-10	1996-12-24	Anthony H. Cincotta	Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5292520A (en) *	1990-09-13	1994-03-08	Akzo N.V.	Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US5225204A (en) *	1991-11-05	1993-07-06	Chen Jivn Ren	Stable dosage of levothyroxine sodium and process of production
IL112106A0 (en) *	1993-12-22	1995-03-15	Ergo Science Inc	Accelerated release composition containing bromocriptine
SI9700186B (sl) *	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6129931A (en) *	1998-09-03	2000-10-10	Isp Investments Inc.	Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
JP2005513080A (ja) *	2001-12-20	2005-05-12	フェムファーマ，インコーポレイテッド	薬物の膣送達
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AU2007216882B2 (en) *	2003-01-02	2010-03-11	Femmepharma Holding Company, Inc.	Pharmaceutical preparations for treatment of diseases and disorders of the breast
JP2006515026A (ja) *	2003-01-02	2006-05-18	フェムファーマホールディングカンパニー，インコーポレイテッド	乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20080153789A1 (en) *	2006-12-26	2008-06-26	Femmepharma Holding Company, Inc.	Topical administration of danazol
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110003000A1 (en) *	2009-07-06	2011-01-06	Femmepharma Holding Company, Inc.	Transvaginal Delivery of Drugs
US8431155B1 (en)	2012-04-30	2013-04-30	Veroscience Llc	Bromocriptine formulations
CN105640901A (zh) *	2014-11-10	2016-06-08	匈牙利吉瑞大药厂	一种利用新型生产工艺制备甲磺酸溴隐亭片的方法及其应用
DK3445362T3 (da)	2016-04-20	2021-10-11	Veroscience Llc	Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
WO2019079623A1 (en)	2017-10-18	2019-04-25	Veroscience Llc	ENHANCED BROMOCRIPTINE FORMULATIONS
US11607455B2 (en)	2019-09-23	2023-03-21	Veroscience Llc	Method for inducing tumor regression
CN117323305B (zh) *	2023-11-07	2024-06-07	杭州沐源生物医药科技有限公司	溴隐亭片剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL113512C (it) *	1962-01-25
US3836618A (en) *	1971-12-23	1974-09-17	American Home Prod	Process for the uniform distribution of a drug on a granulated base
NL7314066A (it) *	1972-10-18	1974-04-22
DE3045135A1 (de) *	1980-11-29	1982-06-09	Sandoz-Patent-GmbH, 7850 Lörrach	Pharmazeutische kompositionen enthaltende bioabbaubare polymere
US4479911A (en) *	1982-01-28	1984-10-30	Sandoz, Inc.	Process for preparation of microspheres and modification of release rate of core material
IE55579B1 (en) *	1982-07-06	1990-11-07	Sterwin Ag	Processes for preparing tablets by a modified'wet-granulation'technique
US4742054A (en) *	1982-11-23	1988-05-03	Naftchi Nosrat E	Treatment of mammals suffering from damage to the central nervous system
GB2154874B (en) *	1984-02-29	1987-11-04	Sandoz Ltd	Bromoscriptine compositions

1989
- 1989-04-07 IT IT8920063A patent/IT1235053B/it active
1990
- 1990-03-30 US US07/502,520 patent/US5066495A/en not_active Expired - Lifetime
- 1990-04-04 DE DE199090106403T patent/DE391374T1/de active Pending
- 1990-04-04 AT AT90106403T patent/ATE114968T1/de not_active IP Right Cessation
- 1990-04-04 DK DK90106403.0T patent/DK0391374T3/da active
- 1990-04-04 EP EP90106403A patent/EP0391374B1/en not_active Expired - Lifetime
- 1990-04-04 ES ES90106403T patent/ES2029776T3/es not_active Expired - Lifetime
- 1990-04-04 DE DE69014691T patent/DE69014691T2/de not_active Expired - Lifetime
- 1990-04-05 DD DD33947390A patent/DD293961B5/de not_active IP Right Cessation
1991
- 1991-09-27 GR GR90300172T patent/GR900300172T1/el unknown

Also Published As

Publication number	Publication date
EP0391374A2 (en)	1990-10-10
DE391374T1 (de)	1991-02-28
DE69014691T2 (de)	1995-04-20
ES2029776T3 (es)	1995-02-01
DK0391374T3 (da)	1995-04-24
IT1235053B (it)	1992-06-17
DE69014691D1 (de)	1995-01-19
US5066495A (en)	1991-11-19
GR900300172T1 (en)	1991-09-27
EP0391374B1 (en)	1994-12-07
ES2029776T1 (es)	1992-10-01
IT8920063A0 (it)	1989-04-07
ATE114968T1 (de)	1994-12-15
EP0391374A3 (en)	1992-07-01

Legal Events

Date	Code	Title
1994-01-27	EP	Request for examination under paragraph 12(1) filed
1994-11-10	B5	Patent specification, 2nd publ. accord. to extension act
1997-12-04	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD293961B5 (de)	1994-11-10	Verfahren zur Herstellung von Tabletten und Kapseln
DE2224534C3 (de)	1981-04-02	Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe
DE69432121T2 (de)	2003-10-16	Bupropion enthaltendes stabilisiertes arzneimittel
DE69232837T3 (de)	2014-01-02	Oxycodonhaltiges Arzneimittel mit verzögerter Wirkstoffabgabe
DE69434479T2 (de)	2006-02-23	Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
DE69311395T2 (de)	1997-10-30	Sphäroidische Arzneimittelformulierung
EP0552227B1 (de)	1995-01-11	Lösungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung und verfahren zu deren herstellung
DE102004011512B4 (de)	2022-01-13	Pharmazeutische Zubereitung enthaltend Pimobendan
DE3710457A1 (de)	1987-10-08	Verbesserung bei pharmazeutisch verwendbaren salzen
CH659467A5 (de)	1987-01-30	Verfahren zur herstellung von nifedipin-trockenpraeparaten.
DD223063A5 (de)	1985-06-05	Verfahren zur herstellung einer teilbaren tablette mit verzoegerter wirkstofffreigabe
DE2530563A1 (de)	1977-01-27	Arzneimittelformulierungen mit geringem missbrauchpotential
EP0265848A1 (de)	1988-05-04	Arzneizubereitungen zur oralen Verabreichung, die als Einzeldosis 10 bis 240 mg Dihydropyridin enthalten
EP1094841B1 (de)	2004-08-18	Pharmazeutische levothyroxinzubereitung
DE2217132A1 (de)	1972-10-26	Festes, oral einzunehmendes Arznei mittel
EP0167909B1 (de)	1992-01-08	Feste Arzneizubereitungen mit Dihydropyridin und Verfahren zu ihrer Herstellung
DE2706660A1 (de)	1978-08-24	Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung
DE2128461A1 (de)	1971-12-16	Pharmazeutisches Präparat
DD253181A5 (de)	1988-01-13	Verfahren zur herstellung einer stabilen nicarandil enthaltenden arzneimittelzubereitung
DE60220436T2 (de)	2008-01-31	Microkügelchen mit einem pleuromutilin-derivat
EP0761210A2 (de)	1997-03-12	Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
DE69907495T2 (de)	2004-05-06	(7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on als reine verbindung
DE60003188T2 (de)	2004-07-01	Paracetamol und drotaverin enthaltende zusammensetzung
DE2849029A1 (de)	1980-05-22	Stabile valepotriat-zubereitungen und verfahren zu deren herstellung
DE112006001853T5 (de)	2008-05-15	Pharmazeutische Zusammensetzungen, die Clopidogrel-Bisulphat enthalten